NEWS

UC San Diego News Center

MENU

News Archive - Scott LaFee

  • Gene Therapy Shows Promise in Treating Neuropathy from Spinal Cord Injuries

    An international team of researchers, led by scientists at UC San Diego, report that a gene therapy that inhibits targeted nerve cell signaling effectively reduced neuropathic pain with no detectable side effects in mice with spinal cord or peripheral nerve injuries.

  • Targeting Molecular Pathway that Causes Pulmonary Arterial Hypertension

    UC San Diego researchers describe the underlying signaling pathway that results in pulmonary arterial hypertension and a novel monoclonal antibody therapy that blocks the abnormal blood vessel formation characterizing the disease.

  • High-Frequency Spinal Cord Stimulation Shows Improved Longer Lasting Pain Relief

    Researchers at UC San Diego School of Medicine report that high-frequency spinal cord stimulation proved more effective at improving perceived pain reduction than low-frequency SCS in patients studied, and that there was some variation in PPR between male and female patients.

  • Study Reveals Genetic Diversity of a Particularly Problematic Pathogen

    Researchers at UC San Diego have used a systems biology approach to parse the genetic diversity of Clostridioides difficile, a particularly problematic pathogen, particularly in health care settings.

  • For Neurons, Where They Begin Isn’t Necessarily Where They End

    Scientists at UC San Diego School of Medicine and Rady Children’s Institute of Genomic Medicine describe novel methods for inferring the movement of human brain cells during fetal development by studying healthy adult individuals who have recently passed away from natural causes.

  • How Ovarian Cancer Defies Immunotherapy

    Researchers at UC San Diego School of Medicine and Moores Cancer Center at UC San Diego Health, with collaborators, have further elucidated how ovarian cancer tumors defy immunotherapy, identifying new molecular targets that might boost immune response.

  • UC San Diego Joins National Trial to Explore New Vaccines for COVID-19 Variants

    UC San Diego has joined a Phase II clinical trial to evaluate various additional COVID-19 booster shots. The trial seeks to understand if different vaccine regimens can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.

  • Landmark Precision Medicine Research Effort Releases its First Genomic Dataset

    The All of Us Research Program, a nationwide effort to gather information from 1 million or more people living in the United States, then use that data to accelerate health research and medical breakthroughs, has published its first genomic dataset.

  • UC San Diego Awarded $38 Million USAID Grant to Improve Global Health Equity

    The U.S. Agency for International Development has funded a $38 million, five-year project led by UC San Diego researchers to better understand and promote health agency for individuals, communities and local organizations in low- and middle-income countries.